girentuximab
mAbexperimental
Girentuximab is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy. — Wikipedia
Clinical trial activity
22 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
13
Phase 3
4
Phase 4
0
Earliest trial started Jul 1, 1997 (NCT00003102)
Timeline
Indications
Studied for
- Arterial Occlusive Diseases · Early Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Chronic Limb-Threatening Ischemia · Early Phase 1
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Kidney Neoplasms · Phase 3
- Mesothelioma · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- von Hippel-Lindau Disease · Phase 2
Mechanism of action
CA9 other
Binds to the CA9 (G250) antigen expressed on the tumour cells, thereby triggering an immune reaction called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this mechanism, effector cells, e.g. NK (natural killer) cells, of the immune system are activated to kill the tumour cells.
- Carbonic anhydrase IXImmunity, passive
CA9 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGirentuximab ↗
- ChEMBLCHEMBL2109668 ↗
- ChEMBLCHEMBL2108320 ↗
- ChEMBLCHEMBL1743027 ↗
Also known as
- 111indium-cg250
- 124i cg250
- 124i-cg250
- 124i girentuximab
- ca9-scan cg250
- cg250
- cg-250
- cg250 (111in)
- cg250 mab
- g250
- g250
- g-250
- g250 mab
- g250 monoclonal antibody
- g250 peptide
- girentuximab
- girentuximab
- girentuximab
- indium
- iodine (124i) girentuximab
- lu177-dota-girentuximab
- monoclonal antibody g250
- rencarex
- wx-g250
- wx-g250
- zr89 girentuximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07179770 | Phase 1 | Sep 15, 2025 | National Cancer Institute (NCI), New York University |
| NCT07077083 | Phase 2 | Aug 1, 2025 | Harvard University, Telix |
| NCT06447103 | Phase 2 | Aug 6, 2024 | Telix, University of California, Los Angeles |
| NCT06204237 | Early Phase 1 (Phase 1) | Feb 1, 2024 | Aplagon Oy, TRACER, University of Groningen |
| NCT05861778 | Phase 1 | Jun 26, 2023 | Grand Pharma (China) Co., Ltd, Peking University, Telix |
| NCT05663710 | Phase 2 | May 30, 2023 | Department of Defense, University of Texas at Houston |
| NCT05563272 | Phase 2 | Nov 15, 2022 | Telix |
| NCT05239533 | Phase 2 | Feb 16, 2022 | Memorial Sloan-Kettering Cancer Center |
| NCT05046665 | Phase 1 | May 14, 2021 | South Metropolitan Health Service, Perth Western Australia, Telix |
| NCT01762592 | Phase 3 | Jun 1, 2017 | Wilex |
| NCT02883153 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2015 | Radboud University |
| NCT01582204 | N/A | Apr 1, 2012 | Cornell University, Wilex |
| NCT02002312 | Phase 2 | Aug 1, 2011 | Radboud University |
| NCT01253668 | Phase 2 | Nov 1, 2010 | University of Pennsylvania |
| NCT00717587 | Phase 2 | Jun 1, 2008 | National Cancer Institute (NCI), University of Pennsylvania |
| NCT00606632 | Phase 3 | Mar 1, 2008 | University of Pennsylvania, Wilex |
| NCT00520533 | N/A | Feb 1, 2008 | Ludwig Institute for Cancer Research, Pfizer, Wilex |
| NCT00602862 | N/A | Jul 1, 2007 | Dutch Cancer Society, Radboud University |
| NCT00199888 | Phase 1 | Feb 1, 2005 | Cornell University, Ludwig Institute for Cancer Research |
| NCT00087022 | Phase 3 | Jul 1, 2004 | University of California, Los Angeles, Wilex |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telix | For profit | 5 | 2 | 2 | 2021 |
| Wilex | For profit | 5 | 3 | 2 | 2004 |
| Cornell University | Academic/Hospital | 3 | 2 | 3 | 1997 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1997 |
| Radboud University | Academic/Hospital | 3 | 3 | 3 | 2007 |
| University of Pennsylvania | Academic/Hospital | 3 | 2 | 2 | 2008 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 2 | 2 | 2 | 2005 |
| University of California, Los Angeles | Academic/Hospital | 2 | 1 | 2 | 2004 |
| Aplagon Oy | For profit | 1 | 1 | 1 | 2024 |
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Grand Pharma (China) Co., Ltd | For profit | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Pfizer | For profit | 1 | 0 | 1 | 2008 |
| South Metropolitan Health Service, Perth Western Australia | Academic/Hospital | 1 | 1 | 1 | 2021 |
| TRACER | For profit | 1 | 0 | 1 | 2024 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2003 |
22 organizations
Page 1 / 2